ストックスクリーナーアプリを入手
2.94
1.43%
0.04
前日終値:
$2.90
開ける：
$2.86
24時間の取引高:
2.01M
Relative Volume:
2.51
時価総額：
$236.84M
収益：
$63.63M
当期純損益:
$10.62M
株価収益率:
58.80
EPS:
0.05
ネットキャッシュフロー:
$-8.64M
1週間 パフォーマンス:
+42.10%
1か月 パフォーマンス:
+64.32%
6か月 パフォーマンス:
+107.14%
1年 パフォーマンス:
+10.16%
1日の値動き範囲:
$2.85
$3.025
1週間の範囲:
$2.08
$3.025
52週間の値動き範囲:
$1.32
$3.10
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
名前
Protalix BioTherapeutics Inc.
セクター
電話
972 4 988 9488
住所
2 Snunit Street, Science Park PO Box 455, Karmiel
PLX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
2.945 | 233.22M | 63.63M | 10.62M | -8.64M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.44 | 119.38B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.62 | 81.46B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
824.09 | 52.65B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.95 | 46.50B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.44 | 38.95B | 4.98B | 69.60M | 525.67M | 0.5198 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-06-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-04-17 | 繰り返されました | Rodman & Renshaw | Buy |
| 2016-04-04 | 開始されました | Rodman & Renshaw | Buy |
| 2015-04-23 | アップグレード | Jefferies | Hold → Buy |
| 2014-11-12 | 繰り返されました | R. F. Lafferty | Buy |
| 2014-01-24 | 開始されました | R. F. Lafferty | Buy |
| 2012-05-02 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | 繰り返されました | Oppenheimer | Outperform |
| 2012-04-30 | ダウングレード | Auriga | Buy → Hold |
| 2011-10-13 | 開始されました | Morgan Joseph | Hold |
| 2011-03-17 | ダウングレード | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | 繰り返されました | Oppenheimer | Outperform |
| 2010-10-14 | 繰り返されました | UBS | Buy |
| 2009-12-02 | 繰り返されました | Hapoalim | Outperform |
| 2009-09-22 | 開始されました | Canaccord Adams | Buy |
| 2009-09-02 | 開始されました | Hapoalim | Outperform |
| 2008-12-01 | 繰り返されました | Oppenheimer | Outperform |
| 2008-03-11 | 開始されました | UBS | Buy |
| 2007-11-20 | 開始されました | CIBC Wrld Mkts | Sector Outperform |
すべてを表示
Protalix BioTherapeutics Inc. (PLX) 最新ニュース
Protalix BioTherapeutics (PLX) Price Target Decreased by 12.00% to 11.22 - Nasdaq
Protalix Biotherapeutics Forms Golden Cross, Signaling Bullish Breakout Ahead - Markets Mojo
PLX: CHMP Delivers Positive Opinion - Yahoo Finance
Protalix says EU panel recommended a new dosing regimen for Fabry disease therapy - MSN
A March Decision That Could Change Protalix BioTherapeutics Outlook - Seeking Alpha
Protalix's New Dosing Regimen Recommended for Approval - intellectia.ai
Protalix (PLX) Surges 14% on Positive EMA Panel Opinion for Elfa - GuruFocus
Protalix rises as EU backs new dosing for Elfabrio (PLX:NYSE) - Seeking Alpha
Protalix (PLX) Gains Positive EMA Opinion for New Elfabrio Dosage - GuruFocus
Protalix Wins EMA Panel Backing for New Elfabrio Dosing - TipRanks
Protalix wins EU panel backing for expanded dosing of Fabry disease drug - Proactive financial news
Protalix BioTherapeutics Announces Positive CHMP Opinion for Elfabrio Dosing Regimen - TradingView
CHMP backs new Elfabrio regimen for Protalix (NYSE: PLX) patients - Stock Titan
Chiesi Global Rare Diseases and Protalix BioTherapeutics - GlobeNewswire
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU - GlobeNewswire
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU - Yahoo Finance
Market movers: Verizon, Sandisk, Protalix Biotherapeutics, American Express… - Proactive financial news
Is Protalix BioTherapeutics Inc. a strong candidate for buy and holdJuly 2025 Retail & Weekly Return Optimization Alerts - mfd.ru
Aug Summary: Should I invest in Rentokil Initial plc Depositary Receipt before earningsJuly 2025 Movers & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Winners Losers: Can Protalix BioTherapeutics Inc sustain its profitabilityM&A Rumor & Consistent Profit Trading Strategies - baoquankhu1.vn
Can Protalix BioTherapeutics Inc. lead its sector in growthPortfolio Performance Summary & Weekly Breakout Watchlists - bollywoodhelpline.com
Analyst Calls: Is PCG.PRH stock influenced by commodity prices2025 Volatility Report & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Aug Selloffs: What is Protalix BioTherapeutics Inc. s 5 year growth outlookJuly 2025 Earnings & Daily Profit Focused Screening - bollywoodhelpline.com
SQZ Biotechnologies (NYSE:SQZ) vs. Protalix BioTherapeutics (NYSE:PLX) Critical Review - Defense World
Protalix, Secarna in agreement to develop rare kidney disorder therapies - MSN
Why Protalix BioTherapeutics Inc. (DE) stock remains stableJuly 2025 Technicals & Risk Adjusted Swing Trade Ideas - Улправда
Will Protalix BioTherapeutics Inc. (PBDA) stock outperform Dow JonesJuly 2025 Big Picture & Short-Term High Return Strategies - ulpravda.ru
Can Protalix BioTherapeutics Inc. stock hit analyst price targetsJuly 2025 WrapUp & Reliable Intraday Trade Plans - Улправда
Will Protalix BioTherapeutics Inc. stock gain from strong economyStop Loss & Target Return Focused Stock Picks - Улправда
Is Protalix BioTherapeutics Inc. (DE) stock dividend growth reliableMarket Performance Recap & High Conviction Trade Alerts - Улправда
Is Protalix BioTherapeutics Inc. (PBDA) stock a safe buy pre earningsJuly 2025 Short Interest & Fast Moving Trade Plans - Улправда
Will Protalix BioTherapeutics Inc. (PBDA) stock sustain dividend payoutsPortfolio Value Report & Daily Chart Pattern Signal Reports - Улправда
Is Protalix BioTherapeutics Inc. (PBDA) stock among top earnings playsWeekly Investment Report & Stepwise Trade Signal Implementation - Улправда
What technical charts say about Protalix BioTherapeutics Inc. stock2025 Support & Resistance & Risk Managed Investment Signals - Улправда
How Low Can Protalix BioTherapeutics Stock Really Go? - Trefis
Why Protalix BioTherapeutics Inc. (DE) stock benefits from AI revolution2026 world cup usa national team qualification young talents pressing system expert forecast preview - ulpravda.ru
Protalix outlines 2026 strategy with focus on uncontrolled gout therapy By Investing.com - Investing.com Nigeria
PLX: Secarna’s antisense oligonucleotide discovery collaboration - MSN
Protalix outlines 2026 strategy with focus on uncontrolled gout therapy - Investing.com India
Protalix BioTherapeutics CEO outlines 2026 priorities, highlights progress across clinical pipeline - Proactive financial news
Protalix BioTherapeutics, Inc. Provides 2026 Strategic Update - TradingView — Track All Markets
Protalix BioTherapeutics Letter to Stockholders - Nasdaq
What’s Driving Mazda Limited Stock’s Recent Momentum Key TrendsSector Performance Drivers & Explosive Profit Growth - earlytimes.in
Market Fear: How strong is Protalix BioTherapeutics Inc DE stock earnings growthWeekly Trade Recap & Community Trade Idea Sharing - Bộ Nội Vụ
Protalix BioTherapeutics (AMEX: PLX)Related Research - intelligentinvestor.com.au
Protalix BioTherapeutics (NYSE:PLX) CEO Buys $101,360.00 in Stock - MarketBeat
Bashan Dror, Protalix BioTherapeutics CEO, buys $101k in shares By Investing.com - Investing.com Canada
Protalix BioTherapeutics (PLX) CEO and director reports 56,000-share stock purchase - Stock Titan
PLX: Secarna's Antisense Oligonucleotide Discovery Collaboration - Research Tree
PLX: Secarna’s Antisense Oligonucleotide Discovery Collaboration - Zacks Small Cap Research
How Protalix BioTherapeutics Inc. (DE) stock reacts to weak economyJuly 2025 Opening Moves & Community Verified Trade Alerts - Улправда
Protalix BioTherapeutics Inc. (PLX) 財務データ
収益
当期純利益
現金流量
EPS
0.43%
2.26%
大文字化:
|
ボリューム (24 時間):